Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Supernus Pharmaceuticals, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 29, a Price to Book Value of 1.80, and an EV to EBITDA of 9.02. In comparison, peers such as PTC Therapeutics, Inc. have a significantly lower P/E of 5.85, while Harmony Biosciences Holdings, Inc. shows a more favorable valuation with a P/E of 11.40.
Despite the overvaluation, Supernus has demonstrated strong recent performance, with a year-to-date return of 38.74%, significantly outpacing the S&P 500's 13.30% return in the same period. However, its longer-term returns, particularly over three and five years, lag behind the broader market, suggesting potential concerns about sustainability at its current valuation levels.